nonspecific ileum terminal ulcer
Conditions
Interventions
experimental group 1:Oral administration of mesalazine
experimental group 2:Oral administration of glutamine
Sponsors
Affiliated Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Sign informed consent voluntarily; 2. Aged 18-70, male or female; 3. Endoscopy shows terminal ileum ulcer; 4. Course of disease exceeds 8 weeks; 5. Laboratory examinations (including blood routine, liver and renal function, electrolyte, ESR, CRP) are normal.
Exclusion criteria
Exclusion criteria: 1. IBD patients; 2. Patients with intestinal tuberculosis; 3. Patients with ischemic bowel disease; 4. Patients with infectious (bacterial, viral and fungal) enteritis; 5. Patients who received NSAIDs, potassium chloride enteric-coated tablets or diuretics in the last 1 month; 6. Patients with eosinophil gastroenteritis; 7. Patients with previous abdominal surgery; 8. Patients with digestive system tumor; 9. Patients with other digestive tract ulcer besides terminal ileum; 10. Pregnancy or lactation; 11. Recent pregnancy planning patients; 12. Those who are allergic to research drugs and have a high sensitivity constitution; 13. Those who are evaluated to be inappropriate for this study by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Electronic colonoscopy;Pathological examination;clinical manifestation; | — |
Secondary
| Measure | Time frame |
|---|---|
| erythrocyte sedimentation rate;C-reactive protein;blood routine examination;T-SPOT;Tuberculosis antibody; | — |
Countries
China
Contacts
Public ContactLiangru Zhu
Affiliated Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
Outcome results
None listed